U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s ...

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...

The biopharma industry has hit a setback in its ambition to leverage President Donald Trump’s “big, beautiful bill” to amend ...

CERo Therapeutics Holdings Inc (NASDAQ:CERO) shares are trading higher Tuesday after the company received U.S. Food and Drug ...

Shares of Cero Therapeutics Holdings drew increased retail investor chatter on Tuesday after the company said that the FDA ...

Capricor Therapeutics has received an orphan drug designation for its drug aimed at potentially treating Becker Muscular Dystrophy. The biotechnology company said Tuesday that the Food and Drug ...

The designation qualifies CERo and CER-1236 for certain incentives, such as FDA assistance in designing clinical trials, access to the FDA Orphan Drug Grants Program, exemption from the drug approval ...

Investing.com -- CERo Therapeutics Holdings Inc (NASDAQ: CERO) stock surged 191.6% after the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for the company’s lead drug ...

The Commissioner's National Priority Voucher (CNPV) programme will be available to companies aligned with pressing matters ...

FDA Commissioner Marty Makary has revealed a new priority review voucher programme for new medicines deemed to be of national ...

Capricor Therapeutics (NASDAQ:CAPR) received the Orphan Drug designation from the U.S. FDA for its lead cell therapy candidate, Deramiocel, to treat becker muscular dystrophy. With its orphan drug ...

CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findingsA follow-up Phase 3 study will be discussed with regulatory authoritiesLUND, ...